(Q43475187)

23 November 2017

title

Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations (English)

1 reference

23 November 2017

A G Maiche

1

1 reference

23 November 2017

L Teerenhovi

series ordinal

2

1 reference

23 November 2017

publication date

1 January 1991

1 reference

23 November 2017

1 reference

23 November 2017

volume

19 Suppl 6

1 reference

23 November 2017

page(s)

S326-9

1 reference

Third generation cephalosporins: safety profiles after 10 years of clinical use.

23 November 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01715773

Safety profile of the quinolones

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01715773

Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group

21 January 2018

1 reference

12 December 2020

Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia

1 reference

12 December 2020

Cefotaxime monotherapy in septicemic patients with hematological malignancies

1 reference

12 December 2020

Study of the influence of protein binding on serum bactericidal titres and killing rates in volunteers receiving ceftazidime, cefotaxime and ceftriaxone

1 reference

12 December 2020

Use of quinolones for the treatment of patients with bacteremia

1 reference

12 December 2020

The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans

1 reference

12 December 2020

Fever and infection in leukemic patients.A study of 494 consecutive patients

1 reference

12 December 2020

Evaluation of cefotaxime alone and in combination with desacetylcefotaxime against strains of Staphylococcus aureus that produce variants of staphylococcal beta-lactamase

1 reference

12 December 2020

Tolerance in patients with terminal renal insufficiency of high doses of cefotaxime

1 reference

12 December 2020

Pathophysiologic basis for the use of third-generation cephalosporins

1 reference

12 December 2020

A review of cephalosporin metabolism: a lesson to be learned for future chemotherapy

1 reference

12 December 2020

Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials

1 reference

12 December 2020

Comparative study of three different dosing regimens of cefotaxime for treatment of gram-negative bacteremia.

1 reference

12 December 2020

Cefotaxime versus ampicillin, methicillin and netilmicin in combination for treatment of febrile episodes in patients with haematologic malignancy

1 reference

12 December 2020

Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis

1 reference

12 December 2020

Comparison of the in vitro action and interaction of cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides spp.

1 reference

12 December 2020

Empiric antibiotic therapy for granulocytopenic cancer patients

1 reference

12 December 2020

Therapy of infection in patients with granulocytopenia

1 reference

12 December 2020

Empirical antimicrobial therapy in the neutropenic host

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01715773

1 reference

23 November 2017

1 reference